Metabolomics identifies and validates serum androstenedione as novel biomarker for diagnosing primary angle closure glaucoma and predicting the visual field progression

Metabolomics identifies and validates serum androstenedione as novel biomarker for diagnosing primary angle closure glaucoma and predicting the visual field progression

Background: Primary angle closure glaucoma (PACG) is the leading cause of irreversible blindness in Asia, and no reliable, effective diagnostic, and predictive biomarkers are used in clinical routines. A growing body of evidence shows metabolic alterations in patients with glaucoma. We aimed to deve...

Full description

Bibliographic Details
Main Authors: Shengjie Li, Jun Ren, Zhendong Jiang, Yichao Qiu, Mingxi Shao, Yingzhu Li, Jianing Wu, Yunxiao Song, Xinghuai Sun, Shunxiang Gao, Wenjun Cao
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2024-02-01
Series:eLife
Subjects:
primary angle closure glaucoma
metabolomics
androstenedione
diagnose
predict
visual field progression
Online Access:https://elifesciences.org/articles/91407

Internet

https://elifesciences.org/articles/91407

Similar Items